Article Information
History
- August 22, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Han Yan1,2,
- Shanbiao Hu3,
- Hedong Zhang3,
- Yangang Zhou1,2,
- Rao Fu1,2,
- Ping Xu1,2,
- Hualin Cai1,2,
- Xi Li4 and
- Gongbin Lan3,#
- 1Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha Hunan, P.R. China 410011
- 2Institute of Clinical Pharmacy, Central South University, Changsha, China
- 3Department of Kidney Transplantation, The Second Xiangya Hospital, Central South University, Changsha Hunan, P.R. China 410011
- 4Department of Clinical Pharmacology, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, Hunan, P.R. China 410008; Institute of Clinical Pharmacology, Central South University; Hunan Key Laboratory of Pharmacogenetics, Changsha Hunan, P.R. China 410008
- ↵#Correspondence: Gongbin Lan, MD, PhD Department of Kidney Transplantation, The Second Xiangya Hospital, Central South University, Changsha Hunan, P.R. China 410011. Phone: +86-0731-85296116 langongbin{at}csu.edu.cn
Posted August 22, 2024.
Optimized tacrolimus dosing strategy in kidney transplant recipients receiving nirmatrelvir-ritonavir for COVID-19
